Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.79 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543706 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL2154519 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL5384624 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL5387857 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL5384625 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL6480661 | 0.86 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL6051353 | 0.85 | HPGD (0.59) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL6475568 | 0.85 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DHPGD | |
| SCHEMBL5607905 | 0.83 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL5388808 | 0.82 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007517820-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1706118-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | claimed |
| WO-2005067929-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-28 | — | — | WO | claimed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2004-03-11 | — | — | US | claimed |
| EP-1355884-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-12-19 | — | — | US | claimed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-6953810-B2 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | PDE4A 13/4885PDE4B 12/4885PDE4C 36/4885 |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | NAMPT, NNT, XDH | PDE4A 701/4885PDE4B 713/4885PDE4C 811/4885 |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | PDE4A 16/4885PDE4B 14/4885PDE4C 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.